Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
1 evidence topic · 6 sources
Summary
Tinlarebant is being developed as an oral treatment for Stargardt disease type 1. DRAGON studied participants aged 12–20 years with established atrophic lesions and visual acuity of 20/200 or better. This trial population should not be equated with a finalized approved population. The sponsor anticipates confirmatory ABCA4 testing, specialty-pharmacy fulfillment, and patient-support programs. These are proposed access arrangements rather than an approved care pathway.